Dataset: Differential expression of immune privilege genes in human pluripotent stem cells and their derivatives

Pluripotent stem cells, including human embryonic stem (hES) and human induced pluripotent stem (hiPS) cells, have been regarded as potential sources for cell-based transplantation therapy. However, the immunogenicity of these cells remains the major determinant for successful clinical application. We therefore studied multiple hES and hiPS cell lines for MHC expression, HLA haplotyping, expression of immune-related genes and T cell activation. The data showed lower levels of MHC class I (MHC-I), b2-microglobulin and HLA-E in undifferentiated stem cells, but the levels were increased to near the levels of somatic cells after co-treatment with interferon gamma. However, the percentages of cells expressing antigen presenting cell markers and MHC-II molecules remained consistently low. Activation of responder lymphocytes by the pluripotent stem cells was significantly lower than by allogeneic lymphocytes in mixed lymphocyte reactions. Finally, the data showed significant differential expression of immune privilege genes (TGF-beta2, Arginase 2, Indo1, GATA3, POMC, VIP, CACLA, CACLB, IL-1RN, CD95L, CR1L, Serpine 1, HMOX1, IL6, LGALS3, HEBP1, THBS1, CD59 and LGALS1) between pluripotent stem cells/derivatives and somatic cells. We concluded that pluripotent stem cell progeny may retain some level of immune privilege and will likely behave in a way different from those of somatic cells after transplantation. Confirmed hiPSC cells and their parental cells were selected for RNA extraction and Affymetrix array analysis. To minimize the clone variation, we selected two clones from each type of iPSC.

Species:

human

Samples:

16

Source:

E-GEOD-28406

Updated:

Dec.12, 2014

Registered:

Jul.12, 2014